Crinetics Pharmaceuticals CRNX Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Crinetics Pharmaceuticals's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Crinetics Pharmaceuticals's financing cash flow?
- Crinetics Pharmaceuticals (CRNX) reported financing cash flow of $389.88M in Q1 2026.
- How has Crinetics Pharmaceuticals's financing cash flow changed year-over-year?
- Crinetics Pharmaceuticals's financing cash flow increased by 8686.9% year-over-year, from $4.44M to $389.88M.
- What is the long-term trend for Crinetics Pharmaceuticals's financing cash flow?
- Over 4 years (2021 to 2025), Crinetics Pharmaceuticals's financing cash flow has grown at a -36.7% compound annual growth rate (CAGR), from $252.68M to $40.61M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.